Publication | Closed Access

Development of isatin-thiazolo[3,2-a]benzimidazole hybrids as novel CDK2 inhibitors with potent in vitro apoptotic anti-proliferative activity: Synthesis, biological and molecular dynamics investigations

Medicinal ChemistryMedicineMolecular Dynamics InvestigationsNovel Cdk2 InhibitorsPharmacological AgentPharmacotherapyAnti-cancer AgentDrug DevelopmentPharmacologyNovel TherapyBiomolecular EngineeringDrug DiscoveryDrug Resistance